As a proof of concept, we aimed to produce first-generation PDCs by conjugating the antimalarial drug primaquine (PQ) onto PDIP. Although PQ is one of the few drugs without clinically relevant resistance, it does not have widespread use because it causes hemolysis in individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), a genetic trait common in malaria-endemic areas. Furthermore, PQ is metabolized into carboxyprimaquine in the body, which does not have any activity against the parasite. The proposed PDC approach provides the potential to deliver PQ directly to the parasite, which could prevent its interaction with healthy tissues and slow the conversion of PQ into inactive byproducts. Further, the combination of the peptide and drug, each with distinct antiplasmodial mechanisms of action, provides the potential to avoid the formation of drug-resistant parasites. Herein, we report the design, synthesis, and biological evaluation of a library of PDIP-PQ conjugates. Various design elements of the PDCs were probed to investigate their effect on biological activity, including: (i) the location of the PDIP conjugation site, (ii) the hydrophilicity of the linker between the peptide and drug, (iii) the spacing between the peptide and drug, and (iv) whether the linker can be cleaved to release the drug cargo under conditions which mimic the intracellular environment of infected RBCs. This work demonstrates that conjugation within the flexible interhelix spacer of PDIP and incorporation of traceless cleavable linkersbearing either a disulfide or trioxolane moietyare important for maintaining the low micromolar potency of the PQ drug cargo against P. falciparum.